Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA SNORD5 (SNORD5) is a member of the C/D box family of small nucleolar RNAs, which are typically involved in the chemical modification and processing of other small nuclear RNAs, primarily through methylation and pseudouridylation of precursor ribosomal RNAs. SNORD5 functions in the nucleolus of eukaryotic cells and serves a housekeeping role in ribosome biogenesis. As an RNA gene, SNORD5 does not encode a protein and is not presently recognized as a therapeutic target or biomarker for disease[7][10][1]. Key points: SNORD5 is a non-coding RNA, not a protein, receptor, or conventional drug target[1][7][10]. It acts in RNA modification, not signal transduction or catalysis. No known involvement in human disease, drug interaction, or use as a clinical biomarker.
Not applicable (no direct drug interactions)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA SNORD5 (SNORD5).